The old and the new in p53 functional regulation

Biochemical and Molecular Medicine

Volumn 62, Issue 1, 1997, Pages 3-10

  Magnelli, Lucia ^a   Ruggiero, Marco ^a   Chiarugi, Vincenzo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Gene regulation; Ionizing radiations; Oncogenes; Signal transduction; Tumor suppressor genes

Indexed keywords

PROTEIN P53;

ATAXIA TELANGIECTASIA; CELL TRANSFORMATION; DNA DAMAGE; GENE MUTATION; GENETIC REGULATION; IONIZING RADIATION; MITOGENICITY; ONCOGENE; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ATAXIA; ATAXIA TELANGIECTASIA;

EID: 0031257441     PISSN: 10773150     EISSN: None     Source Type: Journal    
DOI: 10.1006/bmme.1997.2616     Document Type: Article

References (76)

1. 1. Lane DP. The regulation of p53 function. Steiner Award Lecture. Int J Cancer 57:623-627, 1994.
2. 2. Ozbun MA, Butel JS. Tumour p53 mutations and breast cancer: A critical analysis. Adv Cancer Res 66:71-141, 1995.
3. 3. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7481-7495, 1992.
4. 4. Tishler RB, Calderwood SK, Coleman CM, Price BD. Increases in sequence specific DNA binding by p53 following treatment with chemiotherapeutic and DNA damaging agents. Cancer Res 53:2212-2216, 1993.
5. 5. Ginsberg D, Oren M, Yaniv M, Piette J. Protein binding elements in the promoter region of the mouse p53 gene. Oncogene 5:1285-1290, 1990.
6. 6. Rogel A, Popliker M, Webb CG, Oren M. p53 cellular tumour antigen: Analysis of mRNA levels in normal adult tissues, embryos and tumours. Mol Cell Biol 5:2851-2855, 1985.
7. 7. Louis JM, McFarland VM, May P, Mora PT. The phosphoprotein p53 is down-regulated post-transcriptionally during embryogenesis in vertebrates. Biochim Biopys Acta 950:395-402, 1988.
8. 8. Oren M, Reich NC, Levine AJ. Regulation of the cellular p53 tumour antigen in teratocarcinoma cells and their differentiated progeny. Mol Cell Biol 2:443-449, 1982.
9. 9. Khochbin S, Lawrence J. An antisense RNA involved in p53 mRNA maturation in murine erytroleukemia cells induced to differentiate. EMBO J 8:4107-4114, 1989.
10. 10. Reich NC, Levine A J. Growth regulation of cellular tumour antigen, p53, in non transformed cells. Nature 308:199-201, 1984.
11. 11. Savitzky K, Bar-Shira A, Gilad S, Rotman G, et al. A single Ataxia Telangectasia gene with a product similar to PI3K. Science 268:1749-1753, 1995.
12. 12. Carpenter CL, Cantley, LC. Phosphoinositide kinases. Biochemistry 29:11147-11156, 1990.
13. 13. Monfar L, Lemon LC, Grammar, TC, Cheatham L, Vlahos C, Blenis J. Activation of pp70/85 S6 kinase in interleukin 2 responsive lymphoid cells is mediated by phosphatidyl inositol kinase and inhibited by cAMP. Mol Cell Biol 15:326-337, 1995.
14. 14. Price BD, Youmell MB. The phosphatidyl inositol-3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumour cells to radiation and blocks induction of p53 following DNA damage. Cancer Res 56:246-250, 1996.
15. 15. Kanna KK, Beamish H, Yan J, Habson K, Williams R, Dunn I, Lavin MF. Nature of G1/S cell cycle checkpoint defect in Ataxia Telangectasia. Oncogene 11:609-618, 1995.
16. 16. Shaulsky G, Goldfinger N, Rotter V. Alteration of tumor development in vivo by the expression of wild type and mutated p53. Cancer Res 51:5232-5237, 1991.
17. 17. Takanashi K, Sukuki K. DNA synthesis associated nuclear exclusion of p53 in normal and human breast epithelial cells in culture. Oncogene 9:183-188, 1994.
18. 18. Frieshe M, Haessler C, Bradner G. Induction of nuclear accumulation of the tumor suppressor protein p53 by DNA damaging agents. Oncogene 8:307-318, 1993.
19. 19. Lane DP. A death in the life of p53. Nature 362:786-787, 1993.
20. 20. Oren M, Maltzam W, Levine, AJ. Post translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol 1:101-110, 1981.
21. 21. Rechsteiner M, Rogers SW. PEST sequences and regulation by proteolysis. Trends Biochem Sci 21:267-271, 1996.
22. 22. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Partecipation of the p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991.
23. 23. Nelson WG, Kastan MB. DNA strand breaks: The DNA template alteration that triggers p53-dependent DNA damage response pathway. Mol Cell Biol 14:1815-1823, 1994.
24. 24. Mumnenbrauer T, James F, Muller B, Wiesmuller L, Depper W, Grosse F. p53 protein exhibits a 3′ to 5′ exonuclease activity. Cell 85:1089-1099, 1996.
25. 25. Lee JM, Bernstein A. p53 mutations increase resistance to ionizing radiations. Proc Natl Acad Sci USA 90:5742-5746, 1993.
26. 26. Deppert W. The yin and yang of p53 in cellular proliferation. Cancer Biol 5:187-202, 1994.
27. 27. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for mutant form. EMBO J 9:1595-1602, 1990
28. 28. Stuzbaker HW, Chunakov P, Welch WJ, Jenkins JR. Half-life of mutated p53 isoforms. Oncogene 1:201-211, 1987.
29. 29. Friedman PN, Chen X, Bargonetti J, Prives C. The p53 protein is an unusually shaped tetramer that binds directely to DNA. Proc Natl Acad Sci USA 90:3319-3323, 1993
30. 30. Hupp T, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53. Cell 71:875-886, 1992.
31. 31. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parkson R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75:1-20, 1993.
32. 32. Zambetti GP, Levine AJ. A comparison of the biological activities of wild type and mutant p53. FASEB J 7:855-856, 1993.
33. 33. Milner J, Metcalf EA. Dominant negative mutated p53 isoforms. Cell 75:765-774, 1991.
34. 34. Dittmer D, Pati S, Zambetti G, Chu S, Teresky A, Moore M, Finlay C, Levine AJ. Gain of function mutations in p53. Nature Genet 4:42-46, 1993.
35. 35. Zerrahan J, Deppert W, Weidman D, Patshinsky T, Richards F, Milner J. Correlation between the conformational phenotype of p53 and its subcellular location. Oncogene 7:1371-1381, 1992.
36. 36. Muller BF, Paulsen D, Deppert W. Specific binding of MAR/ SAR DNA elements by mutant p53. Oncogene 12:1941-1952, 1996.
37. 37. Margulies L, Shegal PB. Modulation of human interleukin 6 promoter (IL6) and transcription factor C/EBP beta (NF-IL6) activity by p53 species. J Biol Chem 268:15096-15100, 1993.
38. 38. Kieser A, Weich HA, Bradner G, Marm D, Kolch W. Mutant p53 potentiates PKC induction of vascular endothelial growth factor expression. Oncogene 9:963-969, 1994.
39. 39. Werner H, Konieli E, Rauscher F, Le Roth D. Wild type and mutant p53 differently regulate transcription of the insulin like growth factor receptor gene. Proc Natl Acad Sci USA 93:8318-8323, 1996.
40. 40. Momand J, Zambetti GP, Olson D G, George DL, Levine AJ. The MDM2 oncogene products form complexes with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245, 1992.
41. 41. Oliner JD, Pietempol JA, Tigalingam S, Gyris J, Kinzler, KW, Vogelstein B. Oncoprotein MDM2 cancels the activation domain of tumour suppressor p53. Nature 362:857-860, 1993.
42. 42. Oliner JD, Kinzler KW, Melzer PS, Gerge DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83, 1992.
43. 43. Hupp TR, Lane DP. Regulation of crip tic sequence specific DNA binding protein function of p53 by protein kinases. Cold Spring Harbor Symp Quant Biol 59:195-206, 1994.
44. 44. Milne DM, Palmer RH, Meek DW. Mutation of casein kinase II phosphorylation site abolishes the antiproliferative activity of p53. Nucleic Acids Res 20:5560-5570, 1992.
45. 45. Bischoff JR, Friedman PN, Marsak C, Prives C, Beach D. Human p53 is phosphorylated by p60-cdc2 and cyclin B cdc2. Proc Natl Acad Sci USA 87:4766-4771, 1990.
46. 46. Lees Miller SP, Sakaguki K, Ullrich SJ, Apella E, Anderson CW. Human DNA activated protein kinase phosphorylates serines 15 and 17 in the aminoterminal transactivation domain of human p53. Mol Cell Biol 12:5041-5046, 1992.
47. 47. Milne DM, Campbell, DG, Caudwell, FD, Meek DW. Phosphorylation of tumor suppressor protein p53 by mitogen activated protein kinases. J Biol Chem 269:9253-9260, 1994.
48. 48. Jamal S, Ziff, EB. Raf phosphorylates p53 in vitro and potentiates p53 transcriptional transactivation in vivo. Oncogene 10:2095-2101, 1995.
49. 49. Milne, DM, Cambell, LE, Campbell DG, Meek DW. p53 is phosphorylated in vitro and in vivo by the ultraviolet radiation-induced protein kinase characteristic of the c-jun kinase JNK1. J Biol Chem 270:5511-5518, 1995.
50. 50. Steward N, Hicks GG, Paraskevas F, Movat M. Evidence for a second cell cycle block at G2/M by p53. Oncogene 10:109-115, 1995.
51. 51. Wang Y, Prives C. Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 376:88-91, 1995.
52. 52. Aloni-Grinstein R, Schwartz M, Rotter V. Accumulation of wild type p53 protein upon gamma-irradiation induces a G2 arrest-dependent immunoglobulin K light chain gene expression. .EMBO J 14:1392-1401, 1995.
53. 53. Selivanova G, Wiman KG. p53: A cell cycle regulator activated by DNA damage. Adv Cancer Res 66:143-180, 1995.
54. 54. Jongmans W, Artuso M, Vuillaume M, Bresil H, Jackson S P, Hall J. The role of Ataxia Telangectasia and the DNA-dependent protein kinase in p53 mediated cellular response to ionising radiation. Oncogene 13:1133-1138, 1996.
55. 55. Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequence specific DNA binding function of p53. Cell 80:237-245, 1995.
56. 56. Takenaka I, Morin F, Seizinger BR, and Kley N. Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J Biol Chem 270:5405-5411, 1995.
57. 57. Delphin C, Baudier J. The protein kinase C activator, phorbol ester, cooperates with the wild-type p53 species of ras transformed embryo fibroblasts growth arrest. J Biol Chem 269:29579-29587, 1994.
58. 58. Fishella M, Zambrano N, Ullrich SG, Lin D, Cho B, Mercer E, Ander son CW, Apella E. The carboxyl-terminal serine 392 phosphorylation site of human p53 is not required for wild type activities. Oncogene 9:3249-3252, 1994.
59. 59. Hupp TR, Lane DP. Two distinct signalling pathways activate the latent DNA-binding function of p53 in a casein kinase II-independent manner. J Biol Chem 270:18165-18174, 1995.
60. 60. Milne DM, McKendrick L, Jardine LJ, Deacon E, Lord, JM, Meek DW. Murine p53 is phosphorylated within the Pab 421 epitope by protein kinase C in vitro, but not in vivo, even after stimuli with phorbol ester-o-Tetradecanoyl phorbol 13-acetate. Oncogene 13:205-211, 1996.
61. 61. Castagna M. Phorbol esters as signal transducers and tumour promoters. Biol Cell 59:3-13, 1987.
62. 62. Nishizuka Y. The Albert Lasker Medical Awards. The family of protein kinase C for signal transduction. J Am Med Assoc 262:1826-1833, 1989.
63. 63. Magnelli L, Cinelli M, Chiarugi V. Phorbol esters attenuate the expression of p53 in cells treated by doxorubicin and protects ts-p53/K562 from apoptosis. Biochem Biophys Res Commun 215:641-645, 1995.
64. 64. Skouv J, Jensen PO, Forchhammer J, Larsen JK, Lund LR. Tumor -promoting phorbol ester transiently down-modulates the p53 level and blocks the cell cycle. Cell Growth Differ 5:329-340, 1994.
65. 65. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl M. Wild type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937-948, 1992.
66. 66. Livingstone LR, White A, Sprouse J, Livanos E, Jaks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild type p53. Cell 70:923-935, 1992.
67. 67. Varshavsky A. Phorbol ester dramatically increases incidence of metrotrexate resistant mouse cells: Possible mechanism and relevance to tumor promoters. Cell 25:561-570, 1981.
68. 68. Farber B, Kinzel V. Distribution of phorbol ester TPA induced structural chromosomal aberration in HeLa cells. Carcinogenesis 11:2067-2070, 1990.
69. 69. Farese SV, Konda TS, Davis JR, Standaert ML, Pollet RJ, Cooper DR. Insulin rapidly increases diacylglycerol by activating de novo phosphatidic acid synthesis. Science 236:586-589, 1987.
70. 70. Chiarugi V, Bruni P, Pasquali F, Magnelli L, Basi G, Ruggiero M, Farnararo M. Synthesis of diacylglycerol de novo is responsible for permanent activation and downregulation of protein kinase C in transformed cells Biochem Biophys Res Commun 164:816-823, 1989.
71. 71. Chiarugi V, Magnelli L, Pasquali, Basi G, Ruggiero M. Signal transduction in EJ-H-ras transformed cells: De novo synthesis of diacylglycerol and subversion of agonist stimulated inositol lipid metabolism. FEBS Lett 252:129-134, 1989.
72. 72. Smart RC, Mlls KJ, Hansen LA, Conney AH. Synthetic lipid second messenger sn-1, 2-Didecanoilglycerol: A complete tumor promoter in mouse skin. Cancer Res 49:4455-4458, 1992.
73. 73. Owens MD, Spalding JW, Tennant RW, Smart RC. Genetic alterations cooperate with Ha-ras to accelerate multistage carcinogenesis in TG.AC transgenic mouse skin. Cancer Res 55:3171-3178, 1995.
74. 74. Mills KJ, Reynolds S H, Smart RC. Diacylglycerol is an effector of the clonal expansion of cells containing activated Ha-ras genes. Carcinogenesis 14:2645-2648, 1993.
75. 75. Hendricse C W, Radley S, Donovan DA, Keghley MR, Neoptolemos JP. Activities of phospholipase A2 and diacylglycerol lipase are increased in human colorectal cancer. Br J Surg 82:475-478, 1995.
76. 76. Casamassima F, Pacini S, Dragotto A, Anichini M, Chiarugi V, Ruggiero M. Intracellular diacylglycerol: A mitogenic second messenger proposable as a marker of transformation in squamous cell carcinoma of the lung. Lung Cancer 15:161-170, 1996.